Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-Label, Dose Escalation and Expansion Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Advanced Solid Tumors
Conditions
Interventions
LM-108
An Anti-PD-1 Antibody
Locations
6
United States
Ocala Oncology Center
Ocala, Florida, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Gabrail Cancer and Research Center
Canton, Ohio, United States
The Christ Hospital
Cincinnati, Ohio, United States
University of Oklahoma
Norman, Oklahoma, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
Start Date
May 26, 2022
Primary Completion Date
October 6, 2023
Completion Date
October 6, 2023
Last Updated
October 25, 2023
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT06598800
Lead Sponsor
LaNova Medicines Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions